Lepton Pharmaceuticals announces that it has filed a US application with the US Patent Office entitled METHODS FOR ENHANCED GENOME EDITING

The Patent application covers Lepton’s breakthrough Universal genome editing framework. It is a novel homology directed repair (HDR)-based knock-in (KI) technology named Targeted Replacement Locus Editing (TRIPLE).

Precise genome editing is limited by the low efficiency of HDR compared to the dominant NHEJ pathway. Triple technology can increase the HDR yield many folds over canonical genome editing methods which are not robust with low HDR yield especially on other loci. TRIPLE approach provides a scalable framework for fine-tuning gene expression and offers a novel tool for therapeutic intervention, restoring pathological gene expression patterns with high fidelity.

TRIPLE innovative gene editing approach enables Lepton Castling and is efficient across multiple genomic regions.